NAFLD and liver-related events: does type 2 diabetes have a key role?
Menée à partir de données de 6 cohortes internationales portant sur 2 016 patients atteints d'une stéatose hépatique non alcoolique (53 % de femmes ; âge moyen : 57,8 ans), cette méta-analyse évalue l'association entre un diabète de type 2 et le risque de décompensation hépatique ou de cancer du foie
The global prevalence of non-alcoholic fatty liver disease (NAFLD) is projected to increase substantially in the next decade as the population grows and ages, in parallel with the rising burden of obesity and type 2 diabetes. Cardiovascular disease represents the principal cause of morbidity and mortality among adults with NAFLD; however, the risk of hepatic decompensation and hepato cellular carcinoma increases exponentially with worsening of fibrosis, and liver-related deaths might account for a large proportion of the excess mortality among adults with NAFLD and advanced fibrosis (bridging fibrosis or cirrhosis). Among individuals with NAFLD, those with type 2 diabetes are at higher risk of developing advanced stages of fibrosis and subsequently hepatic decompensation, hepatocellular carcinoma, and liver-related mortality than those without type 2 diabetes.
The Lancet Gastroenterology & Hepatology , commentaire, 2023